Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVE-021
- Development stage
- Preclinical
- Lead developer
- Avenzo Therapeutics
- Modality
- Small Molecules
01
Overview
AVE-021 is a small molecule drug candidate being developed by Avidin Biotech for the treatment of psoriasis. It is currently in the lead optimization phase of development, a stage focused on refining the chemical structure of lead compounds to improve their pharmacological properties, such as potency, selectivity, and metabolic stability. While the specific molecular target of AVE-021 has not been publicly disclosed, it is part of Avidin's pipeline of novel therapeutics aimed at modulating inflammatory pathways. The drug is intended to provide a new therapeutic option for patients suffering from chronic plaque psoriasis.
Beyond the preview
Go deeper on AVE-021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVE-021.